Lassen Therapeutics, LLC
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Lassen Therapeutics, LLC - overview
Established
2019
Location
San Diego, CA, US
Primary Industry
Biotechnology
About
Founded in 2019 and based in California, US, Lassen Therapeutics, LLC operates as a health technology company that develops and manufactures novel medicines for rare diseases. As of 2023, the firm is headed by its CEO Maria Fardis. In December 2023, the firm raised USD 85 million in Series B funding co-led by returning investor Frazier Life Sciences and investor Longitude Capital, with participation from investors BVF Partners and Catalio Capital Management. Returning investors Alta Partners and Longwood Fund also participated in this round.
The company develops antibodies as potential treatments for fibrosis, rare diseases, oncology, and thyroid eye disease. The firm science includes IL-11 which serves as the treatment for fibro-inflammatory diseases such as thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF). The company plans to use the December 2023 funding to support LASN01 clinical program and advance IND-enabling activities for LASN500.
Current Investors
Alta Partners, Longitude Capital, Longwood Fund
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.lassentherapeutics.com/
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.